The role of TG2 in fibrosis is reported to be related to two important effects. The first in mediating the deposition and accumulation of the fibrotic extracellular matrix (ECM) via its cross-linking of proteins like fibronectin, collagen I and collagen III; and the second, the activation of latent matrix bound TGFβ1. We report here that the role of TG2 in fibrosis progression can be much more complex. We also report a new family of TG2-specific inhibitors that can not only inhibit protein cross-linking, but also regulate other functions of TG2, thus increasing their potency which can be demonstrated by their effectiveness in inhibiting fibrosis in two different fibrotic in vivo models.
Griffin, M., Wang, Z., Thibault, T., Murdoch, C., & Rathbone, D. (2015). TG2: a credible therapeutic target in fibrotic diseasedue to its multifunctional roles. Amino Acids, 47(8), 1629. https://doi.org/10.1007/s00726-015-2016-z